ArticleScience translational medicine2024
Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection.
Abstract read
In one paragraph
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial.Scientific reports · 2025Trial
- Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells.Science advances · 2026Article
- Persistent cytolytic CD8Cell reports. Medicine · 2026Article
- Prevalence of Long COVID inJournal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Persistent CD4Cellular immunology · 2026Article
- Implications of RNA virus persistence for post-acute sequelae and chronic inflammatory syndromes.Nature immunology · 2026Review
- Symptom-based clusters in people with post-COVID-19 condition (PCC).Journal of translational medicine · 2026Article
- Neurological impairment in long COVID: implications for neurodegenerative disease.Journal of translational medicine · 2026Review
- Distinct CD8iScience · 2026Article
- Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells.bioRxiv : the preprint server for biology · 2026Article
- Discordant Outcomes of SARS-CoV-2 Exposure in Household Contacts.Clinical immunology communications · 2026Article
- Transcutaneous Auricular Vagus Nerve Stimulation for Post-COVID-19 Condition: A Systematic Review and Critical Appraisal of Clinical Evidence.Journal of clinical medicine · 2026Review
- Reframing ME/CFS: toward a unified mechanistic model of chronic post-infectious diseases.Journal of translational medicine · 2026Review
- Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.EJNMMI research · 2026Review
- Pediatric long COVID is characterized by myeloid CCR6 suppression and immune dysregulation.JCI insight · 2026Article
- Antivirals Targeting Coronavirus RNA-Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID-19 Clinical Trials.Microbial biotechnology · 2026Review
- Persistent Immune Dysregulation during Long COVID is Manifested in Antibodies Targeting Envelope and Nucleocapsid Proteins.Research square · 2026Article
- Post-COVID impairment of memory T cell responses to community-acquired pathogens can be rectified by activating cellular metabolism.bioRxiv : the preprint server for biology · 2026Article
- From HIV to SARS-CoV-2 associated neurological disorder ("HAND" to "SAND"): Viral infection as a "time-bomb" for the aging brain.Neuroscience applied · 2026Review
- Metabolic, viral, and immune phenotypes in long COVID.Frontiers in endocrinology · 2026Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0003-0585-6230
Dylan RyderDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0009-0008-4873-2493
Robert R FlavellDepartment of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-8694-1199
Yingbing WangDepartment of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.
Jelena LeviCellSight Technologies, San Francisco, CA 94107, USA.ORCID 0000-0002-0846-0795
Brian H LaFranchiDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0009-0007-2019-3494
Tyler-Marie DeveauDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0002-9834-8616
Amanda M BuckDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0001-7193-0617
Sadie E MunterDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Kofi A AsareDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Maya AslamDepartment of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.
Walter KochDepartment of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.
Gyula SzaboDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-0493-8437
Rebecca HohDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0001-5112-4220
Monika DeswalDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Antonio E RodriguezDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Melissa BuitragoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0009-0005-3934-6361
Viva TaiDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0003-1415-0766
Uttam ShresthaDepartment of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.
Scott LuDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.
Sarah A GoldbergDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-8642-1468
Thomas DalhuisenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-9132-0496
Joshua J VasquezDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0002-7165-5739
Matthew S DurstenfeldDivision of Cardiology, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0002-7612-3352
Priscilla Y HsueDivision of Cardiology, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0002-3427-6043
J Daniel KellyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.
Nitasha KumarDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0003-1369-3283
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-9773-3256
Aruna GambhirCellSight Technologies, San Francisco, CA 94107, USA.
Ma SomsoukDivision of Gastroenterology, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0001-6116-3645
Youngho SeoDepartment of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-5908-6636
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0001-6371-747X
Zoltan G LaszikDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-0511-8764
Henry F VanBrocklinDepartment of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0003-2849-0841
Timothy J HenrichDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Funding
Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9MEvaluating SARS-CoV-2 spike antigen-induced coagulopathy and neuroinflammation as mechanistic drivers of neurologic PASCR01NS136197 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Michael Joseph Peluso · 2024 to 2026
$2.0MUCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)K12HL143961 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y., HUANG, LAURENCE · 2018 to 2022
$1.8MCharacterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927kPersistent Functional Immune Defects in Treated HIV InfectionK24AI145806 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUNT, PETER W · 2020 to 2024
$921kNHLBI NIH HHS K12 HL143961NIAID NIH HHS K23 AI157875NIAID NIH HHS K24 AI145806NIAID NIH HHS R01 AI141003NINDS NIH HHS R01 NS136197
Abstract
The mechanisms of postacute medical conditions and unexplained symptoms after SARS-CoV-2 infection [Long Covid (LC)] are incompletely understood. There is growing evidence that viral persistence, immune dysregulation, and T cell dysfunction may play major roles. We performed whole-body positron emission tomography imaging in a well-characterized cohort of 24 participants at time points ranging from 27 to 910 days after acute SARS-CoV-2 infection using the radiopharmaceutical agent [
Indexed as
COVID-19Lymphocyte ActivationPositron-Emission TomographyRNA, ViralSARS-CoV-2T-LymphocytesAdultAgedFemaleHumansLungMaleMiddle AgedTime FactorsRNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.